Abivax (ABVX) Interest Expenses (2024 - 2025)

Abivax's Interest Expenses history runs 3 years deep, the most recent figure standing at -$5.6 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 21.05% year-over-year to -$5.6 million; the TTM figure through Mar 2026 stood at $358.7 million (up 683.9% YoY), while the FY2025 annual figure was $130.1 million, up 616.4% from the prior year.
• Interest Expenses for Q1 2026 stood at -$5.6 million, down from $249.4 million in the prior quarter.
• The five-year high for Interest Expenses was $249.4 million in Q4 2025, with the low at -$7.1 million in Q1 2025.
• The 3-year median for Interest Expenses is $7.6 million (2024), against an average of $45.4 million.
• Peak annual rise in Interest Expenses reached 1068.9% in 2025, while the deepest fall reached 253.96% in 2025.
• Abivax's Interest Expenses stood at $35.9 million in 2024, then soared by 594.14% to $249.4 million in 2025, then tumbled by 102.24% to -$5.6 million in 2026.
• Business Quant data shows ABVX's Interest Expenses at -$5.6 million in Q1 2026, $249.4 million in Q4 2025, and $108.8 million in Q3 2025.